Minal Mehta

792 citations

19 papers · 383 indexed · 1 hit paper · h-index 9

Pulmonary and Respiratory Medicine top 10%
Oncology top 10%
Molecular Biology
Cancer Research
Immunology

Co-authors: Danny Nguyen Jianchang Lin Shu Jin Huamao Mark Lin Veronica Bunn Suresh S. Ramalingam Pasi A. Jänne Tarek Mekhail
Topics: Lung Cancer Treatments and Mutations (17 papers)Cancer Genomics and Diagnostics (6 papers)Colorectal Cancer Treatments and Studies (6 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Oncology Annals of Oncology Clinical Pharmacology & Therapeutics
Partner nations: United States Spain China

In The Last Decade

Minal Mehta

19 papers receiving 374 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations Caicun Zhou, Suresh S. Ramalingam et al. JAMA Oncology profile →

Peers

Countries citing papers authored by Minal Mehta

Since Specialization

Citations

This map shows the geographic impact of Minal Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minal Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minal Mehta more than expected).

Fields of papers citing papers by Minal Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minal Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minal Mehta. The network helps show where Minal Mehta may publish in the future.

Co-authorship network of co-authors of Minal Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Minal Mehta. A scholar is included among the top collaborators of Minal Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minal Mehta. Minal Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison 2023 ·Lung Cancer ·Sai‐Hong Ignatius Ou,Huamao Mark Lin,Jin‐Liern Hong,Yu Yin,Shu Jin,Jianchang Lin,Minal Mehta,Pingkuan Zhang,Danny Nguyen,Joel W. Neal	4
2	Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations 2023 ·JTO Clinical and Research Reports ·Sai‐Hong Ignatius Ou,Huamao Mark Lin,Jin‐Liern Hong,Yu Yin,Shu Jin,Jianchang Lin,Minal Mehta,Danny Nguyen,Joel W. Neal	25
3	Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort 2022 ·Journal of Clinical Medicine ·(unknown),Caicun Zhou,Suresh S. Ramalingam,Huamao Mark Lin,Tae Min Kim,Gregory J. Riely,Tarek Mekhail,Danny Nguyen,(unknown),Minal Mehta,Sanjay Popat,Pasi A. Jänne	9
4	Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study 2022 ·Clinical Pharmacology & Therapeutics ·Neeraj Gupta,(unknown),Han Witjes,Paul M. Diderichsen,Steven Zhang,Michael J. Hanley,Jianchang Lin,Minal Mehta	8
5	1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions 2021 ·Annals of Oncology ·Petros Christopoulos,S-H.I. Ou,Jianchang Lin,(unknown),(unknown),Yu Yin,Veronica Bunn,Hui‐Ming Lin,Minal Mehta,Michael Thomas	2
6	1211P Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion 2021 ·Annals of Oncology ·S-H.I. Ou,Huamao Mark Lin,(unknown),Yuping Yin,Shuai Jin,Jianwen Lin,Minal Mehta,Danny Nguyen,Joel W. Neal	2
7	OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations 2021 ·Journal of Thoracic Oncology ·C. Zhou,Suresh S. Ramalingam,(unknown),Jian Fang,(unknown),Sejoong Kim,James Chih‐Hsin Yang,Gregory J. Riely,Tarek Mekhail,Danny Nguyen,(unknown),Enriqueta Felip,Shu Jin,Veronica Bunn,Jianchang Lin,Hui‐Ming Lin,Minal Mehta,Pasi A. Jänne	21
8	Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. 2021 ·Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou,Huamao Mark Lin,Jin‐Liern Hong,Yu Yin,Shu Jin,Jianchang Lin,Minal Mehta,Danny Nguyen,Joel W. Neal	20
9	FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy 2021 ·Journal of Thoracic Oncology ·Pasi A. Jänne,Suresh S. Ramalingam,(unknown),James Chih‐Hsin Yang,Gregory J. Riely,Tarek Mekhail,Danny Nguyen,(unknown),Enriqueta Felip,Shu Jin,Chandi Griffin,Veronica Bunn,Jianchang Lin,Minal Mehta,C. Zhou	2
10	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancerbreakdown → 2021 ·JAMA Oncology ·Caicun Zhou,Suresh S. Ramalingam,Tae Min Kim,Sang‐We Kim,James Chih‐Hsin Yang,Gregory J. Riely,Tarek Mekhail,Danny Nguyen,M.R. García Campelo,Enriqueta Felip,Sylvie Vincent,Shu Jin,(unknown),Veronica Bunn,Jianchang Lin,Huamao Mark Lin,Minal Mehta,Pasi A. Jänne	196
11	1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients 2021 ·Annals of Oncology ·Toyoaki Hida,Masaya Nishino,Kiyotaka Yoh,(unknown),(unknown),(unknown),Minal Mehta,Yuichiro Ohe	1
12	Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. 2021 ·Journal of Clinical Oncology ·Suresh S. Ramalingam,Caicun Zhou,Tae Min Kim,Sang‐We Kim,James Chih‐Hsin Yang,Gregory J. Riely,Tarek Mekhail,Danny Nguyen,M.R. García Campelo,Enriqueta Felip,Sylvie Vincent,Shu Jin,Veronica Bunn,Jianchang Lin,Huamao Mark Lin,Minal Mehta,Pasi A. Jänne	18
13	OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy 2021 ·Journal of Thoracic Oncology ·Alexander I. Spira,(unknown),Joel W. Neal,Zofia Piotrowska,Tarek Mekhail,Anne S. Tsao,Ryan D. Gentzler,Gregory J. Riely,Lyudmila Bazhenova,Shirish M. Gadgeel,(unknown),Melissa L. Johnson,Sylvie Vincent,Shu Jin,Chandi Griffin,Veronica Bunn,Jianchang Lin,Mair E. A. Churchill,Minal Mehta,Pasi A. Jänne	3
14	ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy 2019 ·Annals of Oncology ·Marcus O. Butler,Caroline Robert,Sylvie Négrier,(unknown),John Walker,Ivana Krajsová,Victoria Atkinson,Johan Hansson,Ellen Kapiteijn,Carmen Loquai,Heather M. Shaw,Tina Cheng,Sandrine Mansard,Jean‐Jacques Grob,Massimo Guidoboni,Minal Mehta,Paolo A. Ascierto,Adi Diab	2
15	ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. 2019 ·Journal of Clinical Oncology ·Marcus O. Butler,Caroline Robert,Sylvie Négrier,Gino K. In,John Walker,Ivana Krajsová,Victoria Atkinson,Johan Hansson,Ellen Kapiteijn,Carmen Loquai,Heather M. Shaw,Tina Cheng,Sandrine Mansard,Jean‐Jacques Grob,Massimo Guidoboni,Minal Mehta,Paolo A. Ascierto,Adi Diab	7
16	A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results 2018 ·Annals of Oncology ·Ezra E.W. Cohen,Kevin J. Harrington,David S. Hong,Ricard Mesı́a,Irene Braña,Pedro Pérez Segura,Trisha M. Wise‐Draper,Martin Scott,Pat Mitchell,Ganesh Mugundu,Patricia McCoon,Carl Cook,Minal Mehta,Ulrich Keilholz	30
17	Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) 2017 ·Annals of Oncology ·Ezra E.W. Cohen,David S. Hong,(unknown),William N. William,D. Schrijvers,(unknown),Martin Scott,Paul D. Lyne,Ganesh Mugundu,Patricia McCoon,Carl Cook,Minal Mehta,Ulrich Keilholz	19
18	A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN 2016 ·Annals of Oncology ·David S. Hong,Gerald S. Falchook,Carl Cook,Wael A. Harb,Paul D. Lyne,Patricia McCoon,Minal Mehta,Pat Mitchell,Ganesh Mugundu,Martin Scott,(unknown)	7
19	A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598 2009 ·Journal of Clinical Oncology ·Joan H. Schiller,Suzanne E. Dahlberg,Minal Mehta,David H. Johnson	7

About Minal Mehta

Minal Mehta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 19 papers that have together received 383 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Oncology (290 citations), Pulmonary and Respiratory Medicine (310 citations) and Cancer Research (85 citations). Minal Mehta has collaborated with scholars based in United States, Spain and China. Frequent co-authors include Danny Nguyen, Jianchang Lin, Shu Jin, Huamao Mark Lin, Veronica Bunn, Suresh S. Ramalingam, Pasi A. Jänne, Tarek Mekhail, Gregory J. Riely and Enriqueta Felip. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact